By David Wild
ORLANDO, FLA.-Real-world data from more than 14,000 patients with active cancer and venous thromboembolism (VTE) indicate that apixaban (Eliquis, Bristol-Myers Squibb/Pfizer) is safer and more effective in preventing VTE than low-molecular-weight heparin (LMWH) in this high-risk patient population.